US 12,152,259 B2
Modified CAS9 protein, and use thereof
Osamu Nureki, Bunkyo-ku (JP); Hiroshi Nishimasu, Bunkyo-ku (JP); Hisato Hirano, Bunkyo-ku (JP); Shohei Kajimoto, Bunkyo-ku (JP); Tetsuya Yamagata, Cambridge, MA (US); Yuanbo Qin, Cambridge, MA (US); Keith M. Connolly, Cambridge, MA (US); and Iain Thompson, Cambridge, MA (US)
Assigned to THE UNIVERSITY OF TOKYO, Tokyo (JP); and MODALIS THERAPEUTICS CORPORATION, Tokyo (JP)
Filed by THE UNIVERSITY OF TOKYO, Tokyo (JP); and MODALIS THERAPEUTICS CORPORATION, Tokyo (JP)
Filed on Nov. 25, 2022, as Appl. No. 18/058,823.
Application 18/058,823 is a division of application No. 16/644,378, granted, now 11,530,396, previously published as PCT/JP2018/032948, filed on Sep. 5, 2018.
Claims priority of provisional application 62/724,981, filed on Aug. 30, 2018.
Claims priority of provisional application 62/668,968, filed on May 9, 2018.
Claims priority of provisional application 62/554,227, filed on Sep. 5, 2017.
Prior Publication US 2023/0279374 A1, Sep. 7, 2023
Int. Cl. C12N 9/22 (2006.01); A61K 47/54 (2017.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12N 15/90 (2006.01)
CPC C12N 9/22 (2013.01) [A61K 47/549 (2017.08); C12N 15/11 (2013.01); C12N 15/902 (2013.01); C12N 15/907 (2013.01); C12N 2310/20 (2017.05); C12N 2310/3513 (2013.01); C12N 2800/80 (2013.01)] 15 Claims
 
1. A polynucleotide encoding a protein having at least 80% sequence identity to SEQ ID NO:2 with mutations at the 985-position and the 991-position, and optionally the 986-position,
wherein said protein further comprises:
[I] mutations as at least five sites selected from the group consisting of the 782-position, the 800-position, the 888-position, the 968-position, the 988-position, the 1017-position and the 1021-position; and
(i) mutations at the 927-position and the 929-position,
(ii) a mutation at the 889-position, or
(iii) mutations at the 927-position, the 929-position and the 889-position, and has a binding ability to guide RNA.